Advertisement

New Developments in the pharmacotherapy of schizophrenia

  • W. W. Fleischhacker
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 64)

Abstract

This review summarizes current key research strategies and the most prominently pursued new potential treatments for schizophrenia. First, new routes of administration for second generation antipsychotics are presented. These include rapidly dissolving tablets, drops and sirups as well as new intramuscular formulations. Newly available short acting and long acting (depot) antipsychotics complement oral antipsychotics so that the full spectrum of routes of administration is now available for second generation antipsychotics.

Keywords

Antipsychotic Drug Negative Symptom Schizophrenia Patient Generation Antipsychotic Antipsychotic Polypharmacy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP, The Expert Consensus Panel for Behavioral Emergencies (2001) The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med: 1–88Google Scholar
  2. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mun E (2003) Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 63: 493–512PubMedCrossRefGoogle Scholar
  3. Benkert O, Muller-Siecheneder F, Wetzel H (1995) Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol 5 [Suppl]: 43–53PubMedCrossRefGoogle Scholar
  4. Biglan KM, Holloway RG (2002) A review of pramipexole and its clinical utility in Parkinson’s disease. Exp Opin Pharmacother 3: 197–210CrossRefGoogle Scholar
  5. Brook S (2000) A pilot study of intramuscular ziprasidone in the short-term treatment of patients with acute exacerbation of schizophrenia. Hum Psychopharmacol 15: 521–524PubMedCrossRefGoogle Scholar
  6. Brunot A, Lauchaux B, Sontag H, Casadebaig F, Philippe A, Rouillon F, Clery-Melin P, Hergueta T, Llorca PM, Moreaudefarges T, Guillon P, Lebrun T (2002) Pharmaco-epidemiological study on antipsychotic drug prescription in French psychiatry: patients characteristics, antipsychotic treatment, and care management for schizophrenia. Enc¨¦phale 28: 129–138Google Scholar
  7. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG (2003a) Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (in press)Google Scholar
  8. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW (2003b) Effect of divalproex combined with olanzapine or risperidone in patients with acute exacerbation of schizophrenia. Neuropsychopharmacol 28: 182–192CrossRefGoogle Scholar
  9. Chong SA, Remington GJ, Lee N, Mahendran R (2000) Contrasting clozapine prescribing patterns in the east and west? Ann Acad Med Singapore 29: 75–78PubMedGoogle Scholar
  10. Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28: 75–84PubMedCrossRefGoogle Scholar
  11. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP (2001) Intramuscular (IM) ziprasidone 20mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology 155: 128–134PubMedCrossRefGoogle Scholar
  12. Den Boer JA, van Megen JJGM, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG, Burrows GD, Srivastava ON (1995) Differential effects of the Dl-D A receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology 121: 317CrossRefGoogle Scholar
  13. Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van Laarhoven JH, Busard HL (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double blind trial. Br J Psychiatry 163: 451–455PubMedCrossRefGoogle Scholar
  14. Eerdekens M, Fleischhacker WW, Xie Y, Gefvert O (2002) Long-term safety of long-acting risperidone microspheres. Schizophr Res 53 [Suppl]: 174Google Scholar
  15. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ (2002) Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159: 1596–1598PubMedCrossRefGoogle Scholar
  16. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC (2000) Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157: 826–828PubMedCrossRefGoogle Scholar
  17. Evins AE, Amico E, Posever TA, Toker R, Goff DC (2002) D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 56: 19–23PubMedCrossRefGoogle Scholar
  18. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158: 2071–2074PubMedCrossRefGoogle Scholar
  19. Frieboes RM, Steiger A (2000) The antipsychotic effects of sigma drugs. In: Lidow MS (ed) Neurotransmitter receptors in actions of antipsychotic medication. CRC Press, Boca Raton London New York Washington DC, pp 137–152CrossRefGoogle Scholar
  20. Friedman JI, Temporini H, Davis KL (1999) Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 45: 1–16PubMedCrossRefGoogle Scholar
  21. Gattaz WF, Behrens S, De Vry J, Hafner H (1992) Estradiol inhibits dopamine mediated behavior in rats - an animal model of sex-specific differences in schizophrenia. Fortschr Neurol Psychiatr 60: 8–16PubMedCrossRefGoogle Scholar
  22. Goff DC (2000) Glutamate receptors in schizophrenia and antipsychotic drugs. In: Lidow MS (ed) Neurotransmitter receptors in actions of antipsychotic medication. CRC Press, Boca Raton London New York Washington DC, pp 121–136CrossRefGoogle Scholar
  23. Goff DC, Tsai G, Manoach DS, Coyle JT (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152: 1213–1215PubMedGoogle Scholar
  24. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999a) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56: 21–27CrossRefGoogle Scholar
  25. Goff D et al (1999b) A preliminary dose escalation trial of CX516 (ampakine) added to clozapine in schizophrenia. Cited in: Goff DC (2000) Glutamate receptors in schizophrenia and antipsychotic drugs. In: Lidow MS (ed) Neurotransmitter receptors in actions of antipsychotic medication. CRC Press, Boca Raton London New York Washington DC, pp 121–136Google Scholar
  26. Hausmann A, Fleischhacker WW (2000) Depression in patients with schizophrenia. CNS Drugs 14: 289–299CrossRefGoogle Scholar
  27. Hausmann A, Fleischhacker WW (2002) Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatr Scand 106: 83–96PubMedCrossRefGoogle Scholar
  28. Hawkins JM, Archer KJ, Strakowski SM, Keck PE (1995) Somatic treatment of catatonia. Int J Psychiatry Med 25: 345–369PubMedCrossRefGoogle Scholar
  29. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56: 29–36PubMedCrossRefGoogle Scholar
  30. Javitt DC (2002) Glycine modulators in schizophrenia. Curr Opin Invest Drugs 3: 1067–1072Google Scholar
  31. Javitt DC, Silipo G, Cienfuegos A, Shelly AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR (2001) Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 4: 385–391PubMedCrossRefGoogle Scholar
  32. Joy CB, Mumby-Croft R, Joy LA (2000) Polyunsaturated fatty acids (fish or evening primrose oil) for schizophrenia. Cochrane Database Syst Rev: CD001257Google Scholar
  33. Kane JM, Aguglia E, Altamura AC, Guitierrez JLA, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindström E, Mendlewicz J, Racagni G, Camila IS, Schooler NR (1998) Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 8: 55–66PubMedCrossRefGoogle Scholar
  34. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63: 763–771PubMedCrossRefGoogle Scholar
  35. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003) Long-acting injectible risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry (in press)Google Scholar
  36. Kiivet RA, Llerena A, Dahl ML, Rootslane L, Sanchez Vega J, Eklundh T, Sjoqvist F (1995) Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br J Clin Pharmacol 40: 467–476PubMedCentralPubMedCrossRefGoogle Scholar
  37. Kramer MS, Last B, Getson A, Reines SA (1997) The effects of a selective D4 dopamine receptor antagonist (L 745.870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 54: 567–572PubMedCrossRefGoogle Scholar
  38. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D (1996) A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 20: 247–252PubMedCrossRefGoogle Scholar
  39. Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, Burger H (2002) A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. Arch Women Ment Health 5: 99–104CrossRefGoogle Scholar
  40. Lindamer LA, Buse DC, Lohr JB, Jeste DV (2001) Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 49: 47–51PubMedCrossRefGoogle Scholar
  41. Lingjaerde O (1991) Benzodiazepines in the treatment of schizophrenia: an update survey. Acta Psychiatr Scand 84: 453–459PubMedCrossRefGoogle Scholar
  42. Mahadik SP, Evans D, Lai H (2001) Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 25: 463–493PubMedCrossRefGoogle Scholar
  43. Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58: 538–546PubMedCrossRefGoogle Scholar
  44. McGavin JK, Goa KL (2002) Aripiprazole. CNS Drugs 16: 779–779PubMedCrossRefGoogle Scholar
  45. M¨¹ller MJ, Wetzel H, Eich FX, Rein W, Puech A, Benkert O, Amisulpride Study Group (2002) Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 22: 554–560CrossRefGoogle Scholar
  46. Pappadopulos E, Jensen PS, Schur SB, Maclntyre JC, Ketner S, Van Ordern K, Sverd J, Sardana S, Woodlock D, Schweitzer R, Rube D (2002) “Real world” atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 28: 111–121PubMedCrossRefGoogle Scholar
  47. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK (2001) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49: 243–251PubMedCrossRefGoogle Scholar
  48. Peet M, Horrobin DF, E-E Multicentre Study Group (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 36: 7–18PubMedCrossRefGoogle Scholar
  49. Peuskens J, Van Baelen B, De Smedt C, Lemmens P (2000) Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 15:343–349PubMedCrossRefGoogle Scholar
  50. Peuskens J, Moller HJ, Puech A (2002) Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 12: 305–310PubMedCrossRefGoogle Scholar
  51. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B (1999) Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 156: 145–147PubMedGoogle Scholar
  52. Riecher-Roessler A (2002) Oestrogen effects in schizophrenia and their potential therapeutic implications. Arch Women Ment Health 5: 111–118CrossRefGoogle Scholar
  53. Riecher-Roessler A, Hafner H, Stumbaum M, Schmidt R (1994) Do estrogens have an antipsychotic action? Fortschr Neurol Psychiatr 62: 22–28CrossRefGoogle Scholar
  54. Rittmannsberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H (1999) Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 14: 33–30PubMedCrossRefGoogle Scholar
  55. Rowley H, Kilpatrick I, Needham P, Heal D (1998) Elevation of extracellular cortical norardrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely moving rats. Neuropharmacol 37: 937–944CrossRefGoogle Scholar
  56. Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, Lieberman JA, Lopez-Ibor J J, van Raay B, Twomey E (2002) The usefulness and use of second-generation antipsychotic mediation. Curr Opin Psychiatry 15 [Suppl 1]: S1–S51Google Scholar
  57. Schulz SC, Thompson PA, Jacobs M, Ninan PT, Robinson D, Weiden PJ, Yadalam K, Glick ID, Odbert CL (1999) Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry 60: 366–72PubMedCrossRefGoogle Scholar
  58. See RE (2000) The role of neurotransmitter receptors in the adverse effects of antipsychotic drugs. In: Lidow MS (ed) Neurotransmitter receptors in actions of antipsychotic medication. CRC Press, Boca Raton London New York Washington DC, pp 221–242CrossRefGoogle Scholar
  59. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A (1997) Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 171: 569–573PubMedCrossRefGoogle Scholar
  60. Tandon R, Harrigan E, Zorn SH (1997) Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 4: 159–177Google Scholar
  61. Tollefson GD, Sanger TM, Beasley CM, Tran PV (1998) A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 43: 803–810PubMedCrossRefGoogle Scholar
  62. Ungvari GS, Kau LS, Wai-Kwong T, Shing NF (2001) The pharmacological treatment of catatonia: an overview. Eur Arch Psychiatry Clin Neurosci 251 [Suppl 1]: 131–34Google Scholar
  63. Wassef AA, Dott SG, Harris A, Brown A, O’Boyle M, Meyer WJ 3rd, Rose RM (1999) Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 19: 222–232PubMedCrossRefGoogle Scholar
  64. Wolkowitz OM, Pickar D (1991) Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 148: 714–726PubMedGoogle Scholar
  65. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders JC, Krueger J, Bradley P, San L, Bernardo M, Reinstein M, Breier A (2001) Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 158: 1149–1151PubMedCrossRefGoogle Scholar
  66. Author’s address: W. W. Fleischhacker, MD, Department of Biological Psychiatry, Innsbruck University Clinics, Anichstrasse 35, A-6020 Innsbruck, Austria, e-mail: wolfgang.fleischhacker@uibk.ac.atGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2003

Authors and Affiliations

  • W. W. Fleischhacker
    • 1
  1. 1.Department of Biological PsychiatryInnsbruck University ClinicsInnsbruckAustria

Personalised recommendations